trevena appoints carrie bourdow as chief commercial officer  business wire trevena appoints carrie bourdow as chief commercial officer may    am eastern daylight time king of prussia pabusiness wiretrevena inc nasdaq trvn a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting g protein coupled receptors gpcrs today announced the appointment of carrie l bourdow as senior vice president and chief commercial officer effective immediately “carrie has a fantastic track record of leading successful commercial strategies and brings a wealth of experience in a wide range of therapy areas including neurology and hospital acute care” said maxine gowen phd chief executive officer “her expertise will be invaluable as we advance our growing portfolio and build our company for longterm success” “i am excited to join the trevena team as the company progresses towards commercializing intravenous trv for acute moderate to severe pain” said ms bourdow “the company’s novel research has generated a diverse therapeutic platform and i look forward to providing commercial insight and perspective as trevena develops its phase  programs” ms bourdow brings over  years of experience in pharmaceutical sales and marketing most recently she was vice president of marketing reimbursement and operations at cubist pharmaceuticals inc where she led launch strategy marketing reimbursement and operations for five acute care hospital pharmaceuticals totaling over  billion in annual revenues prior to joining cubist in  ms bourdow served for more than  years at merck  co inc where she held positions of increasing responsibility across several therapeutic areas including antiinfectives acute heart failure and pain ms bourdow has a bachelor of arts degree from hendrix college and earned her masters in business administration from southern illinois university about trevena trevena inc is a clinical stage biopharmaceutical company that discovers develops and intends to commercialize therapeutics that use a novel approach to target g protein coupled receptors or gpcrs using its proprietary product platform trevena is developing four biased ligand product candidates it has identified  trv to treat acute heart failure phase b trv to treat moderate to severe acute pain intravenously phase b trv to treat moderate to severe acute and chronic pain orally phase  and trv for treatmentrefractory migraine and other cns disorders preclinical cautionary note on forward looking statements any statements in this press release about future expectations plans and prospects for the company including statements about the company’s strategy future operations clinical development of its therapeutic candidates plans for potential future product candidates and other statements containing the words “anticipate” “believe” “estimate” “expect” “intend” “may” “plan” “predict” “project” “suggest” “target” “potential” “will” “would” “could” “should” “continue” and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including the status timing costs results and interpretation of the company’s clinical trials the uncertainties inherent in conducting clinical trials whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials expectations for regulatory approvals availability of funding sufficient for the company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements other matters that could affect the viability or commercial potential of the company’s therapeutic candidates the inherent uncertainties associated with intellectual property and other factors discussed in the risk factors set forth in the company’s annual report on form k and quarterly reports on form q filed with the securities and exchange commission sec and in other filings the company makes with the sec from time to time in addition the forwardlooking statements included in this press release represent the company’s views only as of the date hereof the company anticipates that subsequent events and developments may cause the company’s views to change however while the company may elect to update these forwardlooking statements at some point in the future it specifically disclaims any obligation to do so except as may be required by law contacts investor contactstrevena incjonathan violindirector of investor relations xjviolintrevenainccomorargot partnersandrea rabneypresident and chief executive officerandreaargotpartnerscomormedia contactargot partnerseliza schleifsteinelizaargotpartnerscom contacts investor contactstrevena incjonathan violindirector of investor relations xjviolintrevenainccomorargot partnersandrea rabneypresident and chief executive officerandreaargotpartnerscomormedia contactargot partnerseliza schleifsteinelizaargotpartnerscom search advanced news search advanced news search log in sign up carrie bourdow trevena inc profile  biography  bloomberg feedback carrie bourdow senior vpchief commercial ofcr trevena inc career history senior vpchief commercial ofcr trevena inc present vpmarketing reimbursement  operations cubist pharmaceuticals inc former merck  co inc former website wwwtrevenacom corporate information address  west th avenue suite a king of prussia pa  united states phone  fax  web url wwwtrevenacom from the web personal information education hendrix college bachelors degree southern illinois university mba memberships board memberships nabriva therapeutics plc board member present sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data trevena inc appoints carrie bourdow as chief commercial officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       trevena inc trvn appoints carrie bourdow as chief commercial officer tweet   am king of prussia pabusiness wiretrevena inc nasdaq trvn a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting g protein coupled receptors gpcrs today announced the appointment of carrie l bourdow as senior vice president and chief commercial officer effective immediately “i am excited to join the trevena team as the company progresses towards commercializing intravenous trv for acute moderate to severe pain” “carrie has a fantastic track record of leading successful commercial strategies and brings a wealth of experience in a wide range of therapy areas including neurology and hospital acute care” said maxine gowen phd chief executive officer “her expertise will be invaluable as we advance our growing portfolio and build our company for longterm success” “i am excited to join the trevena team as the company progresses towards commercializing intravenous trv for acute moderate to severe pain” said ms bourdow “the company’s novel research has generated a diverse therapeutic platform and i look forward to providing commercial insight and perspective as trevena develops its phase  programs” ms bourdow brings over  years of experience in pharmaceutical sales and marketing most recently she was vice president of marketing reimbursement and operations at cubist pharmaceuticals inc where she led launch strategy marketing reimbursement and operations for five acute care hospital pharmaceuticals totaling over  billion in annual revenues prior to joining cubist in  ms bourdow served for more than  years at merck  co inc where she held positions of increasing responsibility across several therapeutic areas including antiinfectives acute heart failure and pain ms bourdow has a bachelor of arts degree from hendrix college and earned her masters in business administration from southern illinois university about trevena trevena inc is a clinical stage biopharmaceutical company that discovers develops and intends to commercialize therapeutics that use a novel approach to target g protein coupled receptors or gpcrs using its proprietary product platform trevena is developing four biased ligand product candidates it has identified  trv to treat acute heart failure phase b trv to treat moderate to severe acute pain intravenously phase b trv to treat moderate to severe acute and chronic pain orally phase  and trv for treatmentrefractory migraine and other cns disorders preclinical cautionary note on forward looking statements any statements in this press release about future expectations plans and prospects for the company including statements about the company’s strategy future operations clinical development of its therapeutic candidates plans for potential future product candidates and other statements containing the words “anticipate” “believe” “estimate” “expect” “intend” “may” “plan” “predict” “project” “suggest” “target” “potential” “will” “would” “could” “should” “continue” and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including the status timing costs results and interpretation of the company’s clinical trials the uncertainties inherent in conducting clinical trials whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials expectations for regulatory approvals availability of funding sufficient for the company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements other matters that could affect the viability or commercial potential of the company’s therapeutic candidates the inherent uncertainties associated with intellectual property and other factors discussed in the risk factors set forth in the company’s annual report on form k and quarterly reports on form q filed with the securities and exchange commission sec and in other filings the company makes with the sec from time to time in addition the forwardlooking statements included in this press release represent the company’s views only as of the date hereof the company anticipates that subsequent events and developments may cause the company’s views to change however while the company may elect to update these forwardlooking statements at some point in the future it specifically disclaims any obligation to do so except as may be required by law contacts investor contactstrevena incjonathan violindirector of investor relations xjviolintrevenainccomorargot partnersandrea rabneypresident and chief executive officerandreaargotpartnerscomormedia contactargot partnerseliza schleifsteinelizaargotpartnerscom help employers find you check out all the jobs and post your resume read at biospacecom related news trevena inc trvn completes interim analysis and announces plans for ongoing phase b blastahf trial of trv in acute heart failure acucela founder regains top spot at company after shareholder’s meeting trevena inc trvn announces positive results from phase  multiple ascending dose study of trv for moderate to severe acute and chronic pain outgoing ariad aria ceo has no regrets and will work harder than ever until a successor is named trevena inc trvn release trv phase b blastahf trial design published in journal of the american college of cardiology heart failure novartis ag nvs taps cancer guru to head boston rd group that specializes in immunooncology trevena inc trvn reports full year  financial results sanofi sanpa faces backlash over cost of firing and hiring ceos trevena inc trvn initiates second phase b study of trv for acute postoperative pain ovascience ovas stock egged on by executive faith and strong pipeline please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • trevena inc   • biotechpharma  personnel                 trevena appoints carrie bourdow as chief commercial officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street trevena appoints carrie bourdow as chief commercial officer business wire may    am edt trevena inc nasdaq trvn a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting g protein coupled receptors gpcrs today announced the appointment of carrie l bourdow as senior vice president and chief commercial officer effective immediately carrie has a fantastic track record of leading successful commercial strategies and brings a wealth of experience in a wide range of therapy areas including neurology and hospital acute care said maxine gowen phd chief executive officer her expertise will be invaluable as we advance our growing portfolio and build our company for longterm success i am excited to join the trevena team as the company progresses towards commercializing intravenous trv for acute moderate to severe pain said ms bourdow the companys novel research has generated a diverse therapeutic platform and i look forward to providing commercial insight and perspective as trevena develops its phase  programs ms bourdow brings over  years of experience in pharmaceutical sales and marketing most recently she was vice president of marketing reimbursement and operations at cubist pharmaceuticals inc where she led launch strategy marketing reimbursement and operations for five acute care hospital pharmaceuticals totaling over  billion in annual revenues prior to joining cubist in  ms bourdow served for more than  years at merck  co inc where she held positions of increasing responsibility across several therapeutic areas including antiinfectives acute heart failure and pain ms bourdow has a bachelor of arts degree from hendrix college and earned her masters in business administration from southern illinois university about trevena trevena inc is a clinical stage biopharmaceutical company that discovers develops and intends to commercialize therapeutics that use a novel approach to target g protein coupled receptors or gpcrs using its proprietary product platform trevena is developing four biased ligand product candidates it has identified  trv to treat acute heart failure phase b trv to treat moderate to severe acute pain intravenously phase b trv to treat moderate to severe acute and chronic pain orally phase  and trv for treatmentrefractory migraine and other cns disorders preclinical if you liked this article you might like this  biotech stock is making an  move thursday in focus armie margaret lee jul    am edt  beatendown biotechs that should head up synergy pharmaceuticals trevena and egalet seem to have worstcase scenarios priced into them bret jensen jun    am edt biotech movers aratana offering priced below market shares fall aratana therapeutics trevena and sangamo therapeutics were among the biotech stock movers in premarket trading on thursday armie margaret lee may    am edt endo international angiodynamics lead biotech movers endo international slipped  ahead of markets open friday alicia mcelhaney apr    am edt trending apples iphone  is coming and it could be in your hands very soon jim cramer reveals why hes pleased with advanced micro devices and boeings earnings honda accord through the years  reasons the  model is a really big deal if donald trump is right how many jobs would  apple factories in the us really create tesla headlines this lineup of  amazing new cars for  advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers carrie bourdow  trevena inc  zoominfocom carrie bourdows phone  address  peoplebyname contact login home people alphabetically b bourdow carrie bourdow people directory with over  names record id carrie l bourdow barley lnlansdale pa  background check  available record id carrie l bourdow farm wayharleysville pa  background check  available record id carrie l bourdow barley lnlansdale pa age  born  background check  available record id carrie l bourdow farm wayharleysville pa age  born jan  background check  available record id carrie l bourdow farm wayharleysville pa age  born jan  background check  available record id carrie l bourdow barley lnlansdale pa age  born  background check  available record id carrie l bourdow farm wayharleysville pa age  born jan  background check  available record id carrie l bourdow barley lnlansdale pa age  born  background check  available record id carrie l bourdow barley lnlansdale pa  background check  available record id carrie l bourdow farm wayharleysville pa  background check  available record id carrie l bourdow farm wayharleysville pa age  born jan  background check  available record id carrie l bourdow barley lnlansdale pa age  born  background check  available record id carrie l bourdow farm wayharleysville pa age  born jan  background check  available record id carrie l bourdow barley lnlansdale pa age  born  background check  available record id carrie l bourdow farm wayharleysville pa age  born jan  background check  available record id carrie l bourdow barley lnlansdale pa age  born  background check  available      total records available tweet testimonials read testimonials from real customers who already used our services read more webmasters earn  commission on every sale you drive to our website weekly payouts read more mobile version visit us from your smart phone anywhere you are read more recent lookups check out the most recent reverse phone lookups on peoplebynamecom read more home mobile version phone directory people directory remove information terms of service privacy policy affiliate program about us member login frequently asked questions contact us testimonials careers product  services volume discounts site map  peoplebyname all rights reserved  trevena inc menu menu home about trevena about trevena management board of directors careers pipeline our pipeline oliceridine trv moderatetosevere acute pain how oliceridine works oliceridine development trv trv development trv trv platform what is a biased ligand trevenas able platform history of biased ligands investors investor relations press releases investor presentations analyst coverage corporate governance management board of directors committee composition contact the board financials  filings sec filings annual reports and proxies quarterly results stock information historic stock lookup investment calculator investor faqs publications all publications oliceridine publications trv publications biased ligand publications contact contact directions to trevena investor relations press releases investor presentations analyst coverage corporate governance financials  filings stock information investor faqs   corporate presentation investor inquiriesjonathan violin phd vp corporate strategy  ir  x jviolintrevenacom prmedia inquiriesprtrevenacom trevena appoints carrie bourdow as chief commercial officer trevena inc nasdaq trvn a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting g protein coupled receptors gpcrs today announced the appointment of carrie l bourdow as senior vice president and chief commercial officer effective immediately “carrie has a fantastic track record of leading successful commercial strategies and brings a wealth of experience in a wide range of therapy areas including neurology and hospital acute care” said maxine gowen phd chief executive officer “her expertise will be invaluable as we advance our growing portfolio and build our company for longterm success”  “i am excited to join the trevena team as the company progresses towards commercializing intravenous trv for acute moderate to severe pain” said ms bourdow “the company’s novel research has generated a diverse therapeutic platform and i look forward to providing commercial insight and perspective as trevena develops its phase  programs”  ms bourdow brings over  years of experience in pharmaceutical sales and marketing most recently she was vice president of marketing reimbursement and operations at cubist pharmaceuticals inc where she led launch strategy marketing reimbursement and operations for five acute care hospital pharmaceuticals totaling over  billion in annual revenues prior to joining cubist in  ms bourdow served for more than  years at merck  co inc where she held positions of increasing responsibility across several therapeutic areas including antiinfectives acute heart failure and pain ms bourdow has a bachelor of arts degree from hendrix college and earned her masters in business administration from southern illinois university  about trevena trevena inc is a clinical stage biopharmaceutical company that discovers develops and intends to commercialize therapeutics that use a novel approach to target g protein coupled receptors or gpcrs using its proprietary product platform trevena is developing four biased ligand product candidates it has identified  trv to treat acute heart failure phase b trv to treat moderate to severe acute pain intravenously phase b trv to treat moderate to severe acute and chronic pain orally phase  and trv for treatmentrefractory migraine and other cns disorders preclinical cautionary note on forward looking statements any statements in this press release about future expectations plans and prospects for the company including statements about the company’s strategy future operations clinical development of its therapeutic candidates plans for potential future product candidates and other statements containing the words “anticipate” “believe” “estimate” “expect” “intend” “may” “plan” “predict” “project” “suggest” “target” “potential” “will” “would” “could” “should” “continue” and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including the status timing costs results and interpretation of the company’s clinical trials the uncertainties inherent in conducting clinical trials whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials expectations for regulatory approvals availability of funding sufficient for the company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements other matters that could affect the viability or commercial potential of the company’s therapeutic candidates the inherent uncertainties associated with intellectual property and other factors discussed in the risk factors set forth in the company’s annual report on form k and quarterly reports on form q filed with the securities and exchange commission sec and in other filings the company makes with the sec from time to time in addition the forwardlooking statements included in this press release represent the company’s views only as of the date hereof the company anticipates that subsequent events and developments may cause the company’s views to change however while the company may elect to update these forwardlooking statements at some point in the future it specifically disclaims any obligation to do so except as may be required by law  investor contacts trevena incjonathan violindirector investor relations  xjviolintrevenainccom argot partnersandrea rabneypresident and chief executive officer andreaargotpartnerscom media contact argot partnerseliza schleifstein elizaargotpartnerscom about trevena management board of directors careers pipelineolinvo™oliceridine injectiontrvtrv platformable™ platformhistory of biased ligands investors press releases investor presentations analyst coverage corporate governance financials  filings stock information investor faqs publicationsolinvo™trvbiased ligand contactdirections follow us copyright  trevena inc trevena appoints carrie bourdow as chief commercial officer trevena appoints carrie bourdow as chief commercial officer tweet may     am pdt king of prussia pa business wire  trevena inc nasdaq trvn a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting g protein coupled receptors gpcrs today announced the appointment of carrie l bourdow as senior vice president and chief commercial officer effective immediately “carrie has a fantastic track record of leading successful commercial strategies and brings a wealth of experience in a wide range of therapy areas including neurology and hospital acute care” said maxine gowen phd chief executive officer “her expertise will be invaluable as we advance our growing portfolio and build our company for longterm success” “i am excited to join the trevena team as the company progresses towards commercializing intravenous trv for acute moderate to severe pain” said ms bourdow “the company’s novel research has generated a diverse therapeutic platform and i look forward to providing commercial insight and perspective as trevena develops its phase  programs” ms bourdow brings over  years of experience in pharmaceutical sales and marketing most recently she was vice president of marketing reimbursement and operations at cubist pharmaceuticals inc where she led launch strategy marketing reimbursement and operations for five acute care hospital pharmaceuticals totaling over  billion in annual revenues prior to joining cubist in  ms bourdow served for more than  years at merck  co inc where she held positions of increasing responsibility across several therapeutic areas including antiinfectives acute heart failure and pain ms bourdow has a bachelor of arts degree from hendrix college and earned her masters in business administration from southern illinois university about trevena trevena inc is a clinical stage biopharmaceutical company that discovers develops and intends to commercialize therapeutics that use a novel approach to target g protein coupled receptors or gpcrs using its proprietary product platform trevena is developing four biased ligand product candidates it has identified  trv to treat acute heart failure phase b trv to treat moderate to severe acute pain intravenously phase b trv to treat moderate to severe acute and chronic pain orally phase  and trv for treatmentrefractory migraine and other cns disorders preclinical cautionary note on forward looking statements any statements in this press release about future expectations plans and prospects for the company including statements about the company’s strategy future operations clinical development of its therapeutic candidates plans for potential future product candidates and other statements containing the words “anticipate” “believe” “estimate” “expect” “intend” “may” “plan” “predict” “project” “suggest” “target” “potential” “will” “would” “could” “should” “continue” and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including the status timing costs results and interpretation of the company’s clinical trials the uncertainties inherent in conducting clinical trials whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials expectations for regulatory approvals availability of funding sufficient for the company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements other matters that could affect the viability or commercial potential of the company’s therapeutic candidates the inherent uncertainties associated with intellectual property and other factors discussed in the risk factors set forth in the company’s annual report on form k and quarterly reports on form q filed with the securities and exchange commission sec and in other filings the company makes with the sec from time to time in addition the forwardlooking statements included in this press release represent the company’s views only as of the date hereof the company anticipates that subsequent events and developments may cause the company’s views to change however while the company may elect to update these forwardlooking statements at some point in the future it specifically disclaims any obligation to do so except as may be required by law filed in medical pharmaceuticals research biotechnology help us maintain quality content — report this story feed email pdf print contact investor contactstrevena incjonathan violindirector of investor relations xjviolintrevenainccomorargot partnersandrea rabneypresident and chief executive officerandreaargotpartnerscomormedia contactargot partnerseliza schleifsteinelizaargotpartnerscom more read more stories from trevena inc home  about  dlvrit social  browser extension  contact  api  help  tos add your story   insider trading  bourdow carrie l  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  bourdow carrie l select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm trevena inc trvn bourdow carrie lsvp chief commercial officer    direct view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm na trevena inc trvn bourdow carrie lsvp chief commercial officer   direct view option award  pm na trevena inc trvn bourdow carrie lsvp chief commercial officer   direct view option award  am na trevena inc trvn bourdow carrie lsvp chief commercial officer   direct view   secformcom all rights reserved archives        thu  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  trvn carrie l bourdow insider trades for trevena inc bulletin investor alert tokyo markets close in currencies europe markets london markets expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close trevena inc nasdaq trvn go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus trevena inc after hours  quotes are delayed by  min jul    pm trvn quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual carrie l bourdow ms carrie l bourdow is chief commercial officer  senior vice president at trevena inc she received her undergraduate degree from hendrix college and an mba from southern illinois university transactions date shares transaction value     acquisition at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr maxine gowen president chief executive officer  director mr roberto e cuca chief financial officer  senior vice president dr michael w lark chief scientific officer  senior vpresearch dr david soergel chief medical officer  svpclinical development mr john m limongelli secretary senior vice president  general counsel dr yacoub habib svpbusiness development  corporate planning ms carrie l bourdow chief commercial officer  senior vice president dr jonathan violin senior directorinvestor  media relations mr leon o moulder independent chairman dr anne m phillips independent director dr adam m koppel independent director mr jake r nunn independent director mr michael r dougherty independent director ms julie harris mchugh independent director ms barbara yanni independent director log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aoil pauses after bullish data sends price up  for the week so far aasia stocks broadly positive nikkei lifted by nintendo a cities where people are making ridiculous money when they sell their homes pamericans in this field have the highest rate of divorce by age  pthese cashstrapped couples want total strangers to pay for their weddings pthis social network ranks as the worst for young people’s mental health it’s not facebook pmove over breathalyzers ‘textalyzers’ could be used on drivers’ phones pthis is the worst mistake people make at work pcities to move to if you want to work in tech — not including san francisco pwhat donald trump’s battle of wills with jeff sessions teaches you about a difficult boss pwatch out for these surprise charges at the er pthe open road or the open skies millennials choose the former phow an online wedding registry in my name appeared out of thin air pdon’t have a college degree these are the industries with the bestpaid jobs pthe highest paid athletes in the world in one chart phow to teach your kids to be better with money than you are pbacktoschool shopping goes mainstream with deals on eyewear fitness apparel and kitchen appliances psamsung posts record profits on back of strong galaxy s sales pthe dark side of cruises pfor transgender americans workplace discrimination isn’t limited to the military loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice